Startup raises $15M to turn an old diabetes drug into a potent cancer killer

Damian Garde

A group of scientists at UCLA have cooked up some compounds that could harness the -fighting properties of metformin while avoiding the biological hurdles that have limited its effect in past studies. And Enlibrium, a weeks-old , has licensed those assets and raised a $ 15 million in Series A cash to test out the idea.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS